GSK plc (LON:GSK) Given Consensus Recommendation of "Hold" by Analysts

Key Points

• Consensus "Hold" — Seven analysts cover GSK with a split of 1 sell, 3 hold and 3 buy, yielding a consensus 1‑year target price of GBX 2,055.71.
• Trading and valuation snapshot: Shares opened at GBX 1,901 with a market cap of £75.98bn, 50/200‑day moving averages of GBX 2,084/1,925, a P/E of 13.70 and a high debt‑to‑equity of 106.74.
• Insider buying activity: Insiders purchased 15,452 shares in the past 90 days (about $32.1M), including purchases by Jonathan Symonds and Anne Beal, though insiders hold only 0.20% of the stock.

Shares of GSK plc (LON:GSK - Get Free Report) have been assigned a consensus recommendation of "Hold" from the seven ratings firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and three have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is GBX 2,055.71.

Several brokerages recently issued reports on GSK. JPMorgan Chase & Co. reaffirmed an "underweight" rating on shares of GSK in a research report on Wednesday, January 7th. Citigroup upped their target price on GSK from GBX 1,900 to GBX 2,250 and gave the company a "buy" rating in a research report on Monday, February 9th. Shore Capital Group reaffirmed a "buy" rating on shares of GSK in a research report on Wednesday, March 25th. Berenberg Bank reaffirmed a "hold" rating and set a GBX 2,000 target price on shares of GSK in a research report on Thursday, March 26th. Finally, Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and set a GBX 1,900 price target on shares of GSK in a research note on Tuesday, April 28th.

GSK Trading Down 1.4%

Shares of LON:GSK opened at GBX 1,901 on Friday. The business's 50-day moving average is GBX 2,084.34 and its 200 day moving average is GBX 1,925.43. GSK has a 1 year low of GBX 1,288.61 and a 1 year high of GBX 2,282. The firm has a market capitalization of £75.98 billion, a P/E ratio of 13.70, a P/E/G ratio of 1.24 and a beta of 0.35. The company has a debt-to-equity ratio of 106.74, a current ratio of 0.79 and a quick ratio of 0.73.

GSK (LON:GSK - Get Free Report) last announced its earnings results on Wednesday, April 29th. The company reported GBX 46.50 earnings per share (EPS) for the quarter. GSK had a return on equity of 35.78% and a net margin of 17.78%.The company had revenue of GBX 762.90 billion for the quarter. On average, research analysts predict that GSK will post 175.980975 earnings per share for the current fiscal year.

Insider Transactions at GSK

In other news, insider Anne Beal purchased 196 shares of the company's stock in a transaction on Friday, March 20th. The shares were acquired at an average price of GBX 5,179 per share, for a total transaction of £10,150.84. Also, insider Jonathan Symonds purchased 5,000 shares of the company's stock in a transaction on Friday, March 20th. The shares were purchased at an average price of GBX 1,951 per share, for a total transaction of £97,550. Insiders have acquired a total of 15,452 shares of company stock worth $32,135,952 in the last 90 days. 0.20% of the stock is owned by company insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.